PP-372 Characteristics of Adults with Congenital Heart Disease and Pulmonary Arterial Hypertension in the COMPERA-CHD Registry

Conclusion Current COMPERA data indicate that CHD patients * relative to the severity of the disease, are young and have a high exercise capacity, but nonetheless a reduced quality of life * usually are treated with monotherapy * receive ERA more often than PDE-5 inhibitors, and Prostacyclines only exceptionally * receive oral anticoagulation not so often, depending on the type of CHD * have higher survival rates than IPAH patients.